Monday, May 06, 2019 8:36:41 AM
Again, Andy seems to jump the shark every time.
The main reason I think they should have stayed with the dream team is becuse I expect the approval process to become even more difficult now that the FDA knows that he's navigating thru this difficult terrain alone (the FDA can use any excuse because Andy has NO BACK UP), FDA is about to be knee deep in the fight to keep big pharma on top.
They expect this fight because they see how close HEMP/CANNABIS is to becoming recreationally legal, ending the prohibition (people will self medicate because their are less side effects from
H/C). Now dozens of electricueticals about to hit their desk for approvals, things are about to change bigtime for big pharma. Don't worry, the FDA will be right their to prop them up when they get blindsided.
I look at the FDA as the blanky for big pharma. If only Andy had better skills at navigating thru this, obviously he doesn't.
My comments above are simply my opinion and nothing more.
I'm enthusiastic at times however I am NOT a professional trader.
Please contact a financial consultant for investment advice.
ZenaTech, Inc. (NASDAQ: ZENA) Launchs IQ Nano Drone for Commercial Indoor Use • HALO • Oct 10, 2024 8:09 AM
CBD Life Sciences Inc. (CBDL) Targets Alibaba as the Next Retail Giant for Wholesale Expansion of Top-Selling CBD Products • CBDL • Oct 10, 2024 8:00 AM
Foremost Lithium Announces Option Agreement with Denison on 10 Uranium Projects Spanning over 330,000 Acres in the Athabasca Basin, Saskatchewan • FAT • Oct 10, 2024 5:51 AM
Element79 Gold Corp. Reports Significant Progress in Community Relations and Development Efforts in Chachas, Peru • ELEM • Oct 9, 2024 10:30 AM
Unitronix Corp Launches Share Buyback Initiative • UTRX • Oct 9, 2024 9:10 AM
BASANITE INDUSTRIES, LLC RECEIVES U.S. PATENT FOR ITS BASAFLEX™ BASALT FIBER COMPOSITE REBAR AND METHOD OF MANUFACTURING • BASA • Oct 9, 2024 7:30 AM